High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept.
J Vitreoretin Dis
; 7(2): 116-124, 2023.
Article
in En
| MEDLINE
| ID: mdl-37006663
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Vitreoretin Dis
Year:
2023
Document type:
Article
Affiliation country:
United States